---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-067662"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2024-06-03T23:59:59+00:00"
generated_at: "2026-06-01T06:53:02.903208+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cullinan reports Phase 2b zipalertinib data: 39% ORR in post-amivantamab NSCLC patients

## Summary
- ORR of 39% (confirmed) and DCR of 94% in 18 evaluable patients; median DOR and PFS not yet reached.
- No grade 4 or 5 treatment-related adverse events; safety profile manageable and consistent with prior data.
- Data cut-off Jan 12, 2024; patients received median 3 prior therapies including chemo, anti-PD1/L1, and EGFR TKI.
- Enrollment in pivotal REZILIENT1 trial (Modules B2 and C) on track to complete by end of 2024.
- Partnership with Taiho: upfront $275M plus up to $130M in milestones; 50/50 US profit share.

## SEC filing metadata
- accession: 0000950170-24-067662
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2024-06-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000095017024067662/0000950170-24-067662-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000095017024067662/cgem-20240601.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-067662
- JSON: https://secwatch.observer/filing/0000950170-24-067662.json
- Plain text: https://secwatch.observer/filing/0000950170-24-067662.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.